Monopar Therapeutics MNPR Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

46.7%+17.8pp

Eli LillyLLY

102.4%+15.7pp

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

Wave Life SciencesWVE

-68.3%—

Prime MedicinePRME

-373.3%-1,281pp

Perspective TherapeuticsCATX

-39.5%+14.0pp

FAQ

What is Monopar Therapeutics's return on equity?

Monopar Therapeutics (MNPR) reported return on equity of -15.9% in Q1 2026.

How has Monopar Therapeutics's return on equity changed year-over-year?

Monopar Therapeutics's return on equity increased by 70.8% year-over-year, from -54.3% to -15.9%.

What is the long-term trend for Monopar Therapeutics's return on equity?

Over 5 years (2020 to 2025), Monopar Therapeutics's return on equity has grown at a -20.4% compound annual growth rate (CAGR), from -44.5% to -14.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.